SCHEMBL2413552

SCHEMBL2413552

c1ccc2c(c1)cnc1ccncc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.67
GPR3 P46089 1/20 0.67
CYP3A4 P08684 2/20 0.47
MAPK10 P53779 1/20 0.46
HTT P42858 2/20 0.44
LMNA P02545 2/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 1/20 0.44
NCOA1 Q15788 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
CYP1A2 P05177 2/20 0.42
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
TNF P01375 1/20 0.42
POLB P06746 1/20 0.42
RAD52 P43351 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25461085 0.85 MAPK10 (0.50) KDM4EGPR3CYP3A4MAPK10HTT
SCHEMBL29900146 0.84 KDM4E (0.67) KDM4EGPR3CYP3A4MAPK10HTT
SCHEMBL2407348 0.84 KDM4E (0.67) KDM4EGPR3CYP3A4HTTLMNA
SCHEMBL31135312 0.84 KDM4E (0.67) KDM4EGPR3CYP3A4HTTLMNA
SCHEMBL2386455 0.84 KDM4E (0.67) KDM4EGPR3CYP3A4MAPK10HTT
Phenanthridine SCHEMBL28242096 0.82 KDM4E (0.69) KDM4EGPR3CYP3A4MAPK10HTT
Phenanthridine SCHEMBL8666 0.81 GPR3 (1.00) KDM4EGPR3CYP3A4LMNANPC1
Phenanthridine SCHEMBL9106884 0.81 GPR3 (1.00) KDM4EGPR3CYP3A4LMNANPC1
Phenanthridine SCHEMBL30914262 0.81 GPR3 (1.00) KDM4EGPR3CYP3A4LMNANPC1
Phenanthridine SCHEMBL30823553 0.81 GPR3 (1.00) KDM4EGPR3CYP3A4LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-11-09 US disclosed
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-11-09 US disclosed
US-20230151020-A1 HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-05-18 US disclosed
US-20230151020-A1 HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-05-18 US disclosed
US-10472380-B2 Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof PLACON THERAPEUTICS, INC. (US) 2019-11-12 US disclosed
US-20170349615-A1 PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF XLINK THERAPEUTICS, INC. 2017-12-07 US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-9771387-B2 Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof PLACON THERAPEUTICS (US) 2017-09-26 US disclosed
US-20160152646-A1 PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF XLINK THERAPEUTICS, INC. 2016-06-02 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
WO-2014043243-A2 PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BLEND THERAPEUTICS (US) 2014-03-20 WO disclosed
WO-2011105700-A1 NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) 2011-09-01 WO disclosed
US-20080009498-A1 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use NITROMED, INC. (US) 2008-01-10 US disclosed
US-20040087591-A1 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use GARVEY DAVID S (US) 2004-05-06 US disclosed
EP-0988302-B1 BENZONAPHTHYRIDINES ALTANA PHARMA AG (DE) 2003-02-19 EP disclosed
US-RE37234-E1 Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses NITROMED, INC. 2001-06-19 US disclosed
US-6221881-B1 TREATING A SEXUAL DYSFUNCTION NITROMED, INC. 2001-04-24 US disclosed
US-6197778-B1 THERAPY FOR SEXUAL DISORDERS NITROMED, INC. 2001-03-06 US disclosed
US-6172068-B1 SEXUAL DISORDERS NITROMED, INC. 2001-01-09 US disclosed
US-6172060-B1 THERAPY FOR SEXUAL DISORDERS NITROMED, INC. 2001-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349615-A1 PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF TP53, PDCD1LG2, IDH1 KDM4E 4074/4885GPR3 2899/4885CYP3A4 3327/4885
US-20160152646-A1 PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF TP53, PDCD1LG2, IDH1 KDM4E 4074/4885GPR3 2899/4885CYP3A4 3327/4885
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION AOC2, AZI2, KCNH2 KDM4E 995/4885GPR3 3295/4885CYP3A4 1069/4885
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF AHR, ORAI3, WNT3 KDM4E 3942/4885GPR3 8/4885CYP3A4 542/4885
US-20080009498-A1 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use PDE3A, PDE3B, PDE2A KDM4E 1851/4885GPR3 356/4885CYP3A4 745/4885
US-20040087591-A1 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use PDE3A, PDE3B, PDE5A KDM4E 4598/4885GPR3 103/4885CYP3A4 1306/4885
US-20230151020-A1 HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE OCIAD1, OCIAD2, EHD1 KDM4E 2555/4885GPR3 4426/4885CYP3A4 949/4885
US-10472380-B2 Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof TP53, PDCD1LG2, IDH1 KDM4E 4074/4885GPR3 2899/4885CYP3A4 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.